U030 Unlocking Key Dermatologic Clues in Asian Patients
DESCRIPTION
The Asian population in the U.S. is projected to reach 41 million by 2050, comprising 9% of the population. This demographic shift underscores the need for dermatologists to understand the unique presentations of common skin conditions, like atopic dermatitis, in Asian patients. Additionally, rare but serious conditions such as extranodal NK/T-cell lymphoma (nasal type) and Kimura disease are more prevalent in Asian populations. Through a series of over 20 cases, this session will provide key morphologic clues, improve differential diagnosis, and offer an update on therapeutics relevant to dermatologists practicing in the U.S., enhancing care for this growing patient group.
LEARNING OBJECTIVES
Identify distinctive morphologic features of common pediatric and adult inflammatory and neoplastic skin conditions in Asian patients to enhance diagnostic accuracy.
Formulate strategies to approach less prevalent but serious skin conditions that are more commonly seen in Asian populations and understand their differential diagnoses.
Develop evidence-based treatment plans and review current therapeutic approaches for managing these dermatologic conditions in Asian patients.
SCHEDULE
7:30 AM
Pediatric skin conditions in Asians
Joseph Lam
7:45 AM
Immunobullous and systemic conditions in Asians
Ruzeng Xue, MD
8:00 AM
Pigmentary and neoplastic skin conditions in Asians
Harry Liu, MD, FAAD
8:15 AM
Inflammatory skin conditions in Asians
Shinwon Hwang
DIRECTOR
Harry Liu, MD, FAAD
SPEAKERS
Shinwon Hwang
Joseph Lam
Ruzeng Xue, MD
DISCLOSURES
Shinwon Hwang
No financial relationships exist with ineligible companies.
Joseph Lam
AbbVie – Investigator(No Compensation Received); Beiersdorf – Advisory Board(Honoraria); BMJ Best Practice – Other(Honoraria); Celltrion – Advisory Board(Honoraria); CeraVe/Valeante – Advisory Board(Honoraria); Incyte – Advisory Board(Honoraria); Johnson and Johnson – Speaker(Honoraria); La Roche-Posay - L'Oreal Group – Speaker(Honoraria); Medscape – Other(Honoraria); Pfizer Inc. – Investigator(No Compensation Received); Pierre Fabre – Speaker(Honoraria); Sanofi – Investigator(No Compensation Received), Speaker(Honoraria);
Harry Liu, MD, FAAD
Arcutis Biotherapeutics – Advisory Board(Honoraria), Speaker(Honoraria); Celltrion – Speaker/Faculty Education(Honoraria); Incyte – Advisory Board(Honoraria); L'Oreal – Advisory Board(Honoraria); Neutrogena Corporation – Advisory Board(Honoraria); Pfizer Inc. – Speaker/Faculty Education(Honoraria); Sanofi – Advisory Board(Honoraria), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria);
Ruzeng Xue, MD
No financial relationships exist with ineligible companies.